<DOC>
	<DOCNO>NCT03055247</DOCNO>
	<brief_summary>This phase II exploratory study conduct evaluate safety efficacy combination Ibuprofen , G-CSF Plerixafor stem cell mobilization regimen patient affect X-CGD .</brief_summary>
	<brief_title>Combination Ibuprofen , G-CSF Plerixafor Stem Cells Mobilization Regimen Patients Affected X-CGD</brief_title>
	<detailed_description>We design mobilization trial aim collect sufficient number HSPC X-CGD patient ; well know procedure challenge patient , potentially due functional defect induce chronic inflammatory state . The combination G-CSF Plerixafor consider state art HSPC harvest gene therapy trial ; consider add non-steroidal inflammatory drug increase HSPC mobilization reduce inflammation could role alter HSPC content . If trial confirms synergistic effect three drug investigation , regimen consider HSPC mobilization future gene therapy trial X-CGD patient .</detailed_description>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Genetic diagnosis XCGD 1845 year age Karnofsky Index &gt; 80 % Adequate cardiac , renal , hepatic pulmonary function . Negative thrombophilic screen negative history previous thrombotic event Written inform consent Previous Bone Marrow Transplantation previous Gene Therapy . Use investigational agent within 4 week prior study enrolment ( within 6 week use longacting agent ) . Ongoing IFNÎ³ treatment ( within 4 week ) . Symptomatic inflammatory bowel disease . Symptomatic viral , bacterial , fungal infection within 6 week eligibility Neoplasia ( except local skin cancer ) history `` familial '' cancer Myelodysplasia serious hematological disorder History uncontrolled seizure deep venous thrombosis Other systemic disease judge incompatible procedure Positivity HIV and/or HCV RNA and/or HbsAg and/or HBV DNA Active alcohol substance abuse within 6 month study . Contraindications IBU , GCSF , Plerixafor Pantoprazole administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic granulomatous disease X-linked</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>Mobilization regimen</keyword>
	<keyword>Gene Therapy</keyword>
</DOC>